MBI Group announced on Friday that it has completed a project to construct and renovate patient care spaces at The Mount Sinai Hospital's Guggenheim Pavilion, located at 1190 Fifth Avenue on Manhattan's Upper East Side.
The company added that it was selected under a competitive bid process .
Under the four-month project, MBI was responsible for the renovation of patient spaces in the haematology, oncology and bone marrow transplant unit. The renovations of patient rooms, nursing stations, restrooms and corridors included interior demolition, millwork, drywall, ceiling work, tiling, terrazzo, flooring, painting, toilet installation, wall protection, plumbing and HVAC, as well as electrical work.
Founded in 1852, The Mount Sinai Hospital is one of the oldest and largest teaching hospitals in the US. The integrated health care system provides exceptional medical care to local and global communities. It is internationally acclaimed for its excellence in research, patient care, and education across a range of specialties.
Established in 1987, MBI Group is a full-service construction firm providing interior fit-outs and core and shell construction for corporate, educational, healthcare, hospitality, institutional, mixed-use and retail facilities.
Biovica secures European patent for biomarker use in immuno-oncology
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Scancell expands Phase 2 SCOPE trial with new intradermal dosing arm for iSCIB1+
Telix Pharmaceuticals delivers first commercial doses from Belgian manufacturing hub
Innovent presents mazdutide Phase 3 clinical study results at ADA 85th Scientific Sessions
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Aiforia Technologies launches CE-IVD marked AI solution for breast cancer diagnostics
Stockholders approve proposed merger of TuHURA Biosciences and Kineta
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma
Harbour BioMed and Otsuka collaborate on advancing BCMAxCD3 bispecific T-cell engagers
Dizal completes enrolment in sunvozertinib vs. platinum doublet phase III study
RyboDyn joins Lilly Gateway Labs' innovation hub
GRAIL reports positive results from Galleri multi-cancer early detection test registrational study